Balance Sheet
Cash Flow Statement
Capital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashDepreciation & Amortization (CF)Exchange Rate EffectFree Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Moleculin Biotech (MBRX) Free Cash Flow (2016 - 2025)

Moleculin Biotech (MBRX) has 10 years of Free Cash Flow data on record, last reported at -$7.2 million in Q3 2025.

  • For Q3 2025, Free Cash Flow fell 18.16% year-over-year to -$7.2 million; the TTM value through Sep 2025 reached -$22.5 million, up 5.15%, while the annual FY2024 figure was -$23.9 million, 1.09% down from the prior year.
  • Free Cash Flow reached -$7.2 million in Q3 2025 per MBRX's latest filing, down from -$5.6 million in the prior quarter.
  • Across five years, Free Cash Flow topped out at -$3.6 million in Q1 2021 and bottomed at -$8.1 million in Q2 2022.
  • Average Free Cash Flow over 5 years is -$5.9 million, with a median of -$6.0 million recorded in 2024.
  • Peak YoY movement for Free Cash Flow: tumbled 76.7% in 2022, then skyrocketed 36.23% in 2023.
  • A 5-year view of Free Cash Flow shows it stood at -$4.3 million in 2021, then plummeted by 68.09% to -$7.2 million in 2022, then skyrocketed by 32.12% to -$4.9 million in 2023, then fell by 4.16% to -$5.1 million in 2024, then plummeted by 42.1% to -$7.2 million in 2025.
  • Per Business Quant database, its latest 3 readings for Free Cash Flow were -$7.2 million in Q3 2025, -$5.6 million in Q2 2025, and -$4.6 million in Q1 2025.